The invention concerns the use of a protein derived from cancer cells, virus-infected
cells or immune-defence cells or a fragment of said protein, characterized in that
said protein is initially an immunosuppressive and/or angiogenic protein with local
activity and said properties are inactivated by at least 70%, through a physical
and/or chemical treatment, by genetic recombination or by adjuvant conditioning,
said treatment preserving its property of being identified by antibodies directed
afainst said protein, and preserving sufficient immunogenic properties for generating
antibodies neutralizing or blocking said native protein, to obtain a medicine for
use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer
agent. The invention also concerns the resulting immunogenic compounds, their preparation
method and their uses.